How does a patient transition from health to active SLE? This question is the crux of the research conducted by Judith A. James, MD, PhD, and colleagues…

How does a patient transition from health to active SLE? This question is the crux of the research conducted by Judith A. James, MD, PhD, and colleagues…
Will Boggs, MD |
NEW YORK (Reuters Health)—Low-dose methotrexate can be associated with gastrointestinal, pulmonary, infectious, hematologic and other adverse effects, according to an analysis of the Cardiovascular Inflammation Reduction Trial (CIRT). “Methotrexate is not a benign drug, even at dosages used for rheumatic diseases,” Daniel H. Solomon, MD, MPH of Brigham and Women’s Hospital, Boston, tells Reuters Health…
Recent research assessed the risk of gout in patients with type 2 diabetes mellitus prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with those prescribed a glucagon-like peptide-1 (GLP-1) agonist. The study found patients on the SGLT2 inhibitor had a lower rate of gout, suggesting SGLT2 inhibitors may actually reduce the risk of gout among this patient population…
Public health agencies have been raising the profile of arthritis…
During a session at the 2019 ACR/ARP Annual Meeting, Lisa Christopher-Stine, MD, MPH, provided valuable recommendations and practical insights into the care and treatment of myositis patients…
ATLANTA—The authors of the new draft ACR treatment guideline for the management of gout presented the draft guideline on Nov. 13 at the 2019 ACR/ARP Annual Meeting. Based on evidence from more than 130 published studies, there are 42 recommendations, of which 16 were strong, including 27 for urate-lowering therapy (ULT) management, 13 of which…
Shuwei Wang, MD, Gulam A. Manji, MD, PhD, & Anca D. Askanase, MD |
Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) axes have revolutionized therapy and improved survival in advanced cancers. However, these immune system modulators also lead to immune-related adverse events (IRAEs).1,2 In clinical trials, IRAEs mainly involved the gastrointestinal tract, skin, endocrine glands, liver and lung,…
Raj Vachhani, MD, & Angelo L. Gaffo, MD, MSPH |
Case Presentation A 45-year-old man with crystal-proven gout, poorly controlled diabetes and chronic kidney disease was lost to follow-up for six years and presented back to the VA clinic in the midst of a gout flare. He stated he had continued taking 100 mg of allopurinol daily, but his serum urate level was 13.8 mg/dL….
Sirajum Munira, MD, Mamta Sherchan, MD, & Christopher Collins, MD, FACR |
Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease. Although RA develops its central pathology within the synovium of diarthrodial joints, many non-articular organs can be involved, particularly in patients with severe joint disease.1 Although most patients are asymptomatic, cardiac involvement is relatively common and includes rheumatic heart nodules, pericarditis (30–50%), pericardial effusion and…
Funck-Brentano et al. hypothesized that causal associations for osteoarthritis (OA) may differ by site, and they undertook this study to identify causal risk factors of knee, hip and hand OA.